MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-11-2026
RadNet Net Income 2011-2026 | RDNT
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income RadNet
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -18.6 M | 2.79 M | 3.04 M | 10.6 M | 24.7 M | -14.8 M | 14.8 M | 32.2 M | 53 K | 7.23 M | 7.71 M | 1.38 M | 2.12 M | 64.5 M | 7.23 M | 8.39 M | -2.27 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 64.5 M | -18.6 M | 8.89 M |
Quarterly Net Income RadNet
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -33.5 M | 5.42 M | 14.5 M | -37.9 M | - | 3.21 M | -2.98 M | -2.78 M | - | 17.5 M | 8.37 M | -21 M | - | 668 K | 7.9 M | 3.01 M | - | 16.2 M | 2.87 M | 9.46 M | - | 6.16 M | -10.6 M | -16.4 M | 10.4 M | 3.2 M | 4.9 M | -3.73 M | 29.1 M | 5.04 M | 5.41 M | -7.34 M | -7.28 M | 3.23 M | 5.31 M | -1.21 M | 3.68 M | 1.65 M | 3.62 M | -1.72 M | 881 K | 7.99 M | 3.4 M | -4.55 M | 4.2 M | 4.45 M | 5.14 M | -12.4 M | 1.24 M | -467 K | 2.69 M | -1.34 M | 56.6 M | 5.05 M | 2.95 M | -111 K | 4.55 M | 39 K | 3.52 M | -876 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 56.6 M | -37.9 M | 1.95 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Diagnostics research industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
-46.9 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Castle Biosciences
CSTL
|
-24.2 M | $ 19.72 | 2.71 % | $ 572 M |  USA |
 |
Fulgent Genetics
FLGT
|
-42.7 M | $ 16.36 | 2.57 % | $ 495 M | USA |
 |
ICON Public Limited Company
ICLR
|
791 M | $ 114.94 | 1.22 % | $ 9.48 B |  Irlanda |
 |
Agilent Technologies
A
|
1.21 B | $ 113.33 | 2.5 % | $ 34.5 B | USA |
 |
Interpace Biosciences
IDXG
|
24.6 M | $ 1.8 | - | $ 7.96 M | USA |
 |
Celcuity
CELC
|
-177 M | $ 138.86 | 6.03 % | $ 6.49 B | USA |
 |
Co-Diagnostics
CODX
|
-46.9 M | $ 2.31 | 17.26 % | $ 3.07 M | USA |
|
Akumin
AKU
|
-157 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Illumina
ILMN
|
-1.22 B | $ 141.35 | -0.24 % | $ 22.5 B | USA |
 |
Aspira Women's Health
AWH
|
-12.8 K | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
-14.6 M | - | -61.36 % | $ 2.46 M | USA |
 |
Biocept
BIOC
|
-32.1 M | - | -13.05 % | $ 7.29 M | USA |
 |
Guardant Health
GH
|
-416 M | $ 113.24 | 15.33 % | $ 14.2 B | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
-1.81 M | - | - | $ 562 M |  Britain |
 |
CareDx, Inc
CDNA
|
-21.4 M | $ 21.1 | 2.78 % | $ 1.12 B | USA |
 |
Chembio Diagnostics
CEMI
|
-23.3 M | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
4.14 M | - | - | $ 9.42 M |  Israel |
 |
HTG Molecular Diagnostics
HTGM
|
-21.6 M | - | -20.0 % | $ 1.06 M | USA |
 |
Lantheus Holdings
LNTH
|
234 M | $ 96.33 | 3.7 % | $ 6.5 B | USA |
 |
Medpace Holdings
MEDP
|
451 M | $ 421.05 | 0.27 % | $ 12.1 B | USA |
 |
Global Cord Blood Corporation
CO
|
501 M | - | - | $ 399 M |  China |
 |
Mettler-Toledo International
MTD
|
869 M | $ 1 082.63 | 3.03 % | $ 22.3 B |  Schweiz |
 |
Fluidigm Corporation
FLDM
|
-53 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
-7.13 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
-503 M | - | 0.12 % | $ 80.1 M | China |
 |
National Research Corporation
NRC
|
11.6 M | $ 19.2 | 2.4 % | $ 430 M | USA |
 |
Natera
NTRA
|
-548 M | $ 202.96 | 3.53 % | $ 20 B | USA |
 |
DermTech
DMTK
|
-101 M | - | -11.32 % | $ 2.94 M | USA |
 |
Charles River Laboratories International
CRL
|
-144 M | $ 156.38 | 2.59 % | $ 7.75 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
197 M | - | - | $ 10.7 B | USA |
 |
Personalis
PSNL
|
-81.3 M | $ 7.86 | 11.58 % | $ 701 M | USA |
 |
Enzo Biochem
ENZ
|
-26.1 M | - | -8.98 % | $ 14.8 K | USA |
 |
NeoGenomics
NEO
|
-108 M | $ 8.79 | 4.77 % | $ 1.13 B | USA |
 |
Exact Sciences Corporation
EXAS
|
-208 M | - | - | $ 19.8 B | USA |
 |
Myriad Genetics
MYGN
|
-366 M | $ 3.74 | 5.21 % | $ 346 M | USA |
 |
Heska Corporation
HSKA
|
-19.9 M | - | - | $ 1.31 B | USA |
 |
Koninklijke Philips N.V.
PHG
|
897 M | $ 26.76 | 2.71 % | $ 25.4 B |  Niderland |
 |
Thermo Fisher Scientific
TMO
|
6.7 B | $ 449.72 | 0.43 % | $ 170 B | USA |
 |
Senseonics Holdings
SENS
|
-69.1 M | $ 5.69 | 2.62 % | $ 237 M | USA |
 |
Twist Bioscience Corporation
TWST
|
-77.7 M | $ 54.25 | 9.6 % | $ 3.24 B | USA |
 |
QIAGEN N.V.
QGEN
|
425 M | - | - | $ 10.6 B | Niderland |
 |
Soleno Therapeutics
SLNO
|
20.9 M | - | - | $ 2.69 B | USA |
 |
Biomerica
BMRA
|
-4.97 M | $ 2.35 | -1.26 % | $ 5.4 M | USA |
 |
Trinity Biotech plc
TRIB
|
-31.2 M | $ 0.6 | 6.65 % | $ 216 M | Irlanda |
 |
Laboratory Corporation of America Holdings
LH
|
876 M | $ 257.11 | 1.35 % | $ 21.4 B | USA |
 |
Motus GI Holdings
MOTS
|
-12.9 M | - | -34.28 % | $ 263 K | Israel |
 |
Waters Corporation
WAT
|
643 M | $ 341.81 | 2.57 % | $ 20.4 B | USA |
 |
Neogen Corporation
NEOG
|
-1.09 B | $ 8.73 | 4.49 % | $ 1.89 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
992 M | $ 193.73 | 1.75 % | $ 21.5 B | USA |